68220-26-8

Basic information

• Product Name: 2-CHLORO-6-FLUOROBENZYL BROMIDE
• Synonyms: ALPHA-BROMO-2-CHLORO-6-FLUOROTOLUENE;2-BROMOMETHYL-1-CHLORO-3-FLUORO-BENZENE;2-CHLORO-6-FLUOROBENZYL BROMIDE;2-Chloro-6-fluorobenzyl bromide, 97+%;2-Chloro-6-Florobenzyl Bromide;Benzene, 2-(bromomethyl)-1-chloro-3-fluoro-;à-bromo-2-chloro-6-fluorotoluene;2-Chloro-6-fluorobenzyl bromide 97%
• CAS NO: 68220-26-8
• Molecular Formula: C₇H₅BrClF
• Molecular Weight: 223.4700032
• EINECS: -0
• Product Categories: Aromatic Halides (substituted);Aryl;C7;Halogenated Hydrocarbons;Fluorine series
• Mol File: 68220-26-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 222 °C at 760 mmHg
• Flash Point: >230 °F
• Appearance: Colorless to yellow/Liquid
• Density: 1.629 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.155mmHg at 25°C
• Refractive Index: n20/D 1.568(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-CHLORO-6-FLUOROBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-FLUOROBENZYL BROMIDE(68220-26-8)
• EPA Substance Registry System: 2-CHLORO-6-FLUOROBENZYL BROMIDE(68220-26-8)

Safety Data

• Hazard Codes: Xi,C
• Statements: 36/37/38
• Safety Statements: 26-36/37-37/39
• RIDADR: 3265
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 68220-26-8(Hazardous Substances Data)

Usage

Uses

2-Chloro-6-fluorobenzyl bromide [2-(bromomethyl)-1-chloro-3-fluorobenzene] may be used in the synthesis of 4-chlorobenzoimidazo[1,2-a][3,1]benzothiazine.

InChI:InChI=1/C7H5BrClF/c8-4-5-6(9)2-1-3-7(5)10/h1-3H,4H2

Upstream product

• 434-75-3 2-chloro-6-fluorobenzoic acid 
• 56456-50-9 (2-chloro-6-fluorophenyl)methanol 

Downstream Products

• 76850-27-6 1-(2-Chloro-6-fluoro-benzyl)-4-oxy-1H-pyrazin-2-one 
• 76850-41-4 2-(2-Chloro-6-fluoro-benzyloxy)-pyrazine 4-oxide 
• 72564-76-2 6-chloro-9-(2-chloro-6-fluorobenzyl) purine 
• 170378-95-7 2,2'-difluoro-6,6'-dichlorobibenzyl 
• 880549-34-8 5-bromo-1-(2-chloro-6-fluoro-benzyl)-1H-pyrimidine-2,4-dione 
• 867288-05-9 1,3-Dibromo-2-(2-chloro-6-fluoro-benzyloxy)-5-nitro-benzene 
• 616882-02-1 N-tert-butoxycarbonylamino-O-(2-chloro-6-fluorobenzyl)-D-serine 
• 867288-06-0 C₁₃H₈Cl₂FNO₃ 
• 632626-70-1 3-{2-[5-bromo-2-(2-chloro-6-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid ethyl ester 
• 374921-30-9 8-bromo-7-(2-chloro-6-fluorobenzyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione 
• 1186653-42-8 2,4-dimethyl-6-[(2-chloro-6-fluorophenyl)methyl]-4H-thieno[3,2-b]pyrrole[3,2-d]pyridazinone 

Relevant articles and documents

Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor

The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, so far, few selective SMS2 inhibitors and their pharmacological activities were reported. In this study, a class of 2-benzyloxybenzamides were discovered as novel SMS2 inhibitors through scaffold hopping and structural optimization. Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 μM against purified SMS2 and SMS1 respectively. The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1. The in vitro studies indicated that Ly93 not only dose-dependently diminished apoB secretion from Huh7 cells, but also significantly reduced the SMS activity and increased cholesterol efflux from macrophages. Meanwhile, Ly93 inhibited the secretion of LPS-mediated pro-inflammatory cytokine and chemokine in macrophages. The pharmacokinetic profiles of Ly93 performed on C57BL/6J mice demonstrated that Ly93 was orally efficacious. As a potent selective SMS2 inhibitor, Ly93 significantly decreased the plasma SM levels of C57BL/6J mice. Furthermore, Ly93 was capable of dose-dependently attenuating the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice treated with Ly93. In conclusion, we discovered a novel selective SMS2 inhibitor Ly93 and demonstrated its anti-atherosclerotic activities in vivo. The preliminary molecular mechanism-of-action studies revealed its function in lipid homeostasis and inflammation process, which indicated that the selective inhibition of SMS2 would be a promising treatment for atherosclerosis.

N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists

The nuclear retinoic acid receptor-related orphan receptor γ (RORγ; NR1F3) is a key regulator of inflammatory gene programs involved in T helper 17 (TH17) cell proliferation. As such, synthetic small-molecule repressors (inverse agonists) targeting RORγ have been extensively studied for their potential as therapeutic agents for various autoimmune diseases. Alternatively, enhancing TH17 cell proliferation through activation (agonism) of RORγ may boost an immune response, thereby offering a potentially new approach in cancer immunotherapy. Herein we describe the development of N-arylsulfonyl indolines as RORγ agonists. Structure–activity studies reveal a critical linker region in these molecules as the major determinant for agonism. Hydrogen/deuterium exchange coupled to mass spectrometry (HDX-MS) analysis of RORγ–ligand complexes help rationalize the observed results.